DarioHealth Corp. (DRIO)
NASDAQ: DRIO · Real-Time Price · USD
14.05
-1.28 (-8.35%)
Oct 29, 2025, 4:00 PM EDT - Market closed
DarioHealth Revenue
DarioHealth had revenue of $5.37M in the quarter ending June 30, 2025, a decrease of -14.16%. This brings the company's revenue in the last twelve months to $27.15M, up 41.79% year-over-year. In the year 2024, DarioHealth had annual revenue of $27.04M with 32.86% growth.
Revenue (ttm)
$27.15M
Revenue Growth
+41.79%
P/S Ratio
1.41
Revenue / Employee
$134,396
Employees
202
Market Cap
95.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 27.04M | 6.69M | 32.86% |
| Dec 31, 2023 | 20.35M | -7.30M | -26.41% |
| Dec 31, 2022 | 27.66M | 7.14M | 34.82% |
| Dec 31, 2021 | 20.51M | 12.94M | 170.76% |
| Dec 31, 2020 | 7.58M | 17.00K | 0.22% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
DRIO News
- 16 days ago - Dario Signs 6 New Employer Clients Representing Tens of Thousands of Lives Deepening its Leadership in Value-Based Care - PRNewsWire
- 23 days ago - DarioHealth and OneStep Announce Strategic Collaboration to Integrate Smartphone-Only, Clinical-Grade Fall Risk Assessment Technology into Dario's Digital Health Multi-Condition Platform - PRNewsWire
- 5 weeks ago - DarioHealth Announces Strategic Review Following Multiple Unsolicited Inbound Expressions of Interest - PRNewsWire
- 5 weeks ago - DarioHealth Announces $17.5 Million Private Placement of Common Stock Priced At-The-Market Under Nasdaq Rules - PRNewsWire
- 2 months ago - DarioHealth Issues Shareholder Update: Multi-Condition Leadership in Momentum Driven Digital Health Market - PRNewsWire
- 2 months ago - Dario Secures Five New Employer Contracts Across Cardiometabolic Suite Including its Largest Employer to Date, Contributing to Annual Recurring Revenues Beginning Q3 2025 - PRNewsWire
- 2 months ago - DarioHealth Announces 20-to-1 Reverse Stock Split - PRNewsWire
- 2 months ago - DarioHealth Corp. (DRIO) Q2 2025 Earnings Call Transcript - Seeking Alpha